Frae Wikipedia
Jump to navigation Jump to search
INN: Metamfetamine
An eemage o the methamphetamine compoond
Baw-an-stick model o the methamphetamine molecule
Clinical data
Pronunciation /ˌmɛθæmˈfɛtəmn/
Tred names Desoxyn
AHFS/ monograph
Leecence data
  • US: C (Risk nae ruled oot)
Pheesical: none
Psychological: heich
Routes o
Medical: oral (ingestion), intravenous[1]
Recreational: oral, intravenous, intramuscular, subcutaneous, smeuk inhalation, insufflation, rectal, vaginal
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: 70%[2]
IV: 100%[2]
Protein bindin Varies widely[3]
Metabolism CYP2D6[4] and FMO3[5]
Onset o action Rapid[6]
Biological hauf-life 5–30 oors[7]
Duration o action 10–20 oors[6]
Excretion Primarily renal
Synonyms N-methylamphetamine, N,α-dimethylphenethylamine, desoxyephedrine
CAS Nummer
PubChem CID
PDB ligand
ECHA InfoCard 100.007.882
Chemical and physical data
Formula C10H15N
Molar mass 149.24 g·mol−1
3D model (Jmol)
Chirality Racemic mixtur
Meltin pynt 3 °C (37 °F) (predicted)[8]
Bylin pynt 212 °C (414 °F) at 760 mmHg[9]

Methamphetamine (contractit frae N-methylamphetamine) is a strang central nervish seestem (CNS) stimulant that is mainly uised as a recreational drog an less commonly as a treatment for attention deficit hyperactivity disorder an obesity.

References[eedit | eedit soorce]

  1. United States Congress Senate Committee on the Judiciary Subcommittee to Investigate Juvenile Delinquincy (1 January 1972). Amphetamine legislation 1971: Hearings, Ninety-second Congress, first session, pursuant to S. Res. 32, section 12, investigation of juvenile delinquency in the United States (PDF). U.S. Govt. Print. Off. p. 161. Retrieved 1 January 2016. We made a decision in January of 1969 to cease the manufacture of injectable methamphetamines. 
  2. 2.0 2.1 Rau T, Ziemniak J, Poulsen D (2015). "The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury". Prog. Neuropsychopharmacol. Biol. Psychiatry. 64: 231–6. doi:10.1016/j.pnpbp.2015.02.013. PMID 25724762. In humans, the oral bioavailability of methamphetamine is approximately 70% but increases to 100% following intravenous (IV) delivery (Ares-Santos et al., 2013). 
  3. "Toxicity". Methamphetamine. PubChem Compound. National Center for Biotechnology Information. Retrieved 31 December 2013. 
  4. "Adderall XR Prescribing Information" (PDF). United States Food and Drug Administration. December 2013. pp. 12–13. Retrieved 30 December 2013. 
  5. Krueger SK, Williams DE (June 2005). "Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism". Pharmacol. Ther. 106 (3): 357–387. doi:10.1016/j.pharmthera.2005.01.001. PMC 1828602Freely accessible. PMID 15922018. 
  6. 6.0 6.1 Riviello, Ralph J. (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. p. 41. ISBN 9780763744625. 
  7. Schep LJ, Slaughter RJ, Beasley DM (August 2010). "The clinical toxicology of metamfetamine". Clinical Toxicology (Philadelphia, Pa.). 48 (7): 675–694. doi:10.3109/15563650.2010.516752. ISSN 1556-3650. PMID 20849327. 
  8. "Properties: Predicted – EP|Suite". Methmphetamine. Chemspider. Retrieved 3 January 2013. 
  9. "Chemical and Physical Properties". Methamphetamine. PubChem Compound. National Center for Biotechnology Information. Retrieved 31 December 2013.